Form 4: DiaMedica Therapeutics Director Acquires Shares and Stock Options

Director Randall Michael Giuffre reports acquisition of shares and stock options in DiaMedica Therapeutics.

Summary

• On June 1, 2024, Randall Michael Giuffre, a director of DiaMedica Therapeutics Inc., acquired 28,472 stock options with an exercise price of $2.90, vesting quarterly over one year and expiring on May 31, 2034.
• Giuffre directly owns 364,551 voting common shares, which includes shares issuable upon settlement of deferred share units and shares held jointly with his wife and individually.
• He indirectly owns 25,573 voting common shares through 424822 Albert Ltd, where he has sole voting and dispositive power.
• His spouse also holds 21,070 voting common shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard Form 4 filing. The acquisition of stock options by a director can be seen as a mildly positive sign, but it's not a major event.

Positives

• The director's acquisition of stock options could be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry. Investors often monitor these filings for signals about management's confidence in the company.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates